Covered recipient · General Payments record
JOHN OGHENE
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$786.82
- Reported across 36 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $742.07 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $173.02 | 5 |
| Amgen Inc. | $152.76 | 8 |
| ABBVIE INC. | $137.31 | 8 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $66.78 | 2 |
| Xeris Pharmaceuticals, Inc. | $45.33 | 2 |
| GlaxoSmithKline, LLC. | $40.88 | 2 |
| Organon LLC | $30.21 | 2 |
| GENZYME CORPORATION | $29.02 | 1 |
| Sandoz Inc. | $24.16 | 1 |
| E.R. Squibb & Sons, L.L.C. | $22.50 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $20.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 2018
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $3.51 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147206 | CMS |
| ABBVIE INC. | $26.99 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147208 | CMS |
| ABBVIE INC. | $14.66 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147210 | CMS |
| ABBVIE INC. | $14.63 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147212 | CMS |
| ABBVIE INC. | $8.28 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147214 | CMS |
| ABBVIE INC. | $14.37 | 11/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147216 | CMS |
| ABBVIE INC. | $29.55 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147218 | CMS |
| ABBVIE INC. | $25.32 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105147220 | CMS |
| Amgen Inc. | $16.82 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664936 | CMS |
| Amgen Inc. | $26.94 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664928 | CMS |
| Amgen Inc. | $7.49 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664930 | CMS |
| Amgen Inc. | $6.77 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664932 | CMS |
| Amgen Inc. | $26.68 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117342446 | CMS |
| Amgen Inc. | $23.01 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664938 | CMS |
| Amgen Inc. | $22.06 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664934 | CMS |
| Amgen Inc. | $22.99 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111664940 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.49 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118046636 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.29 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118046638 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.50 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101306969 | CMS |
| GENZYME CORPORATION | $29.02 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139989265 | CMS |
| GlaxoSmithKline, LLC. | $19.63 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116611473 | CMS |
| GlaxoSmithKline, LLC. | $21.25 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116450869 | CMS |
| Novartis Pharmaceuticals Corporation | $20.10 | 12/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087343605 | CMS |
| Organon Llc | $10.48 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136200671 | CMS |
| Organon Llc | $19.73 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136200673 | CMS |
| Sandoz Inc. | $24.16 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089365641 | CMS |
| UCB, Inc. | $17.37 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143235607 | CMS |
| UCB, Inc. | $0.92 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153142337 | CMS |
| UCB, Inc. | $20.42 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143235611 | CMS |
| UCB, Inc. | $20.01 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143235615 | CMS |
| UCB, Inc. | $114.30 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153142339 | CMS |
| Xeris Pharmaceuticals, Inc. | $20.78 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144599386 | CMS |
| Xeris Pharmaceuticals, Inc. | $24.55 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144599384 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.